Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200251 | 1.00 | CYP2A6 (0.43) | CYP2A6CYP11B1CYP11B2CHRNB2CHRNB4 | |
| SCHEMBL25816479 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2HCAR2 | |
| SCHEMBL30020231 | 0.81 | CHRNB4 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL27040478 | 0.81 | CHRNB4 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL30020787 | 0.81 | CHRNB4 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL30020269 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2HCAR2 | |
| SCHEMBL30020800 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2HCAR2 | |
| SCHEMBL31200474 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2HCAR2 | |
| SCHEMBL27040925 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2HCAR2 | |
| SCHEMBL25816494 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | CYP2A6 3197/4885CYP11B1 2940/4885CYP11B2 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.